[go: up one dir, main page]

CO4650042A1 - Derivados de 6-fenilpiridil-2-amina - Google Patents

Derivados de 6-fenilpiridil-2-amina

Info

Publication number
CO4650042A1
CO4650042A1 CO97015141A CO97015141A CO4650042A1 CO 4650042 A1 CO4650042 A1 CO 4650042A1 CO 97015141 A CO97015141 A CO 97015141A CO 97015141 A CO97015141 A CO 97015141A CO 4650042 A1 CO4650042 A1 CO 4650042A1
Authority
CO
Colombia
Prior art keywords
alkyl
phenyl
independently selected
aryl
ring
Prior art date
Application number
CO97015141A
Other languages
English (en)
Inventor
Lowe John Adams
Peter John Whittle
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CO4650042A1 publication Critical patent/CO4650042A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a ciertos derivados de 6-fenil-piridin-2-ilamina que presentan actividad como inhibidores de la óxido nítrico sintasa (NOS), a composiciones farmacéuticas que los contienen y a su uso en el tratamiento y prevención de trastornos del sistema nervioso central.Un compuesto de la fórmulay las sales farmacéuticamente aceptables del mismo, en la que R1 y R2 se seleccionan, independientemente, entre alquilo (Cl -C6 ), tetrahidronaftaleno y aralquilo, donde el radical arilo de dicho aralquilo es fenilo o naftilo y donde dicho alquilo (C1 -C6 ), dicho grupo tetrahidronaftaleno o el anillo arilo de dicho grupo aralquilo opcionalmente puede estar sustituido con uno a tres sustituyentes que se seleccionan, independientemente, entre halo, nitro, hidroxi, ciano, amino, alcoxi (C1 -C4 ) y alquilamino (C1 -C4 ); o R1 y R2 forman, junto con el nitrógeno al que están unidos, un anillo de piperazina, piperidina o pirrolidina o un anillo azabicíclico que contiene de 6 a 14 miembros en el anillo, de los cuales de 1 a 3 son nitrógenos y el resto son carbonos; y donde dichos anillos de piperazina, piperidina y pirrolidina opcionalmente pueden estar sustituidos con uno más sustituyentes;n es 0, 1 ó 2; m es O, 1 ó 2; cada R8 y cada R9 se seleccionan, independientemente, entre alquilo(C1 -C4 ) y aril-alquilo(C1 -C4 ), donde dicho arilo se selecciona entre fenilo y naftilo; alilo y fenalilo; X e Y se seleccionan, independientemente, entre metilo, metoxi, hidroxi e hidrógeno; y R10 es alquilo (C1 -C6 );con la condición de que R8 esté ausente cuando n es cero y R9 esté ausente cuando m es cero; o una sal farmacéuticamente aceptable de tal compuesto.
CO97015141A 1996-03-29 1997-03-20 Derivados de 6-fenilpiridil-2-amina CO4650042A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1434396P 1996-03-29 1996-03-29

Publications (1)

Publication Number Publication Date
CO4650042A1 true CO4650042A1 (es) 1998-09-03

Family

ID=21764907

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97015141A CO4650042A1 (es) 1996-03-29 1997-03-20 Derivados de 6-fenilpiridil-2-amina

Country Status (43)

Country Link
US (2) US6235747B1 (es)
EP (2) EP1471055A1 (es)
JP (1) JP3455229B2 (es)
KR (1) KR100313641B1 (es)
CN (2) CN1546470A (es)
AP (1) AP677A (es)
AR (1) AR006391A1 (es)
AT (1) ATE261942T1 (es)
AU (1) AU729129B2 (es)
BG (1) BG64310B1 (es)
BR (1) BR9708386A (es)
CA (1) CA2250372C (es)
CO (1) CO4650042A1 (es)
CZ (1) CZ291647B6 (es)
DE (1) DE69728138T2 (es)
DK (1) DK0891332T3 (es)
DZ (1) DZ2197A1 (es)
EA (1) EA002270B1 (es)
ES (1) ES2214604T3 (es)
GT (1) GT199700033A (es)
HR (1) HRP970174B1 (es)
HU (1) HUP9902455A3 (es)
ID (1) ID17116A (es)
IL (1) IL125811A (es)
IS (1) IS4823A (es)
MA (1) MA26424A1 (es)
MY (1) MY118283A (es)
NO (1) NO312460B1 (es)
NZ (2) NZ326874A (es)
OA (1) OA10873A (es)
PE (1) PE55098A1 (es)
PL (1) PL329195A1 (es)
PT (1) PT891332E (es)
SI (1) SI0891332T1 (es)
SK (1) SK113998A3 (es)
TN (1) TNSN97055A1 (es)
TR (1) TR199801930T2 (es)
TW (1) TW438793B (es)
UA (1) UA49006C2 (es)
UY (1) UY24503A1 (es)
WO (1) WO1997036871A1 (es)
YU (1) YU12097A (es)
ZA (1) ZA972689B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199801930T2 (xx) * 1996-03-29 1998-12-21 Pfizer Inc. 6-Fenilpiridil-2-amin t�revleri.
HN1997000027A (es) 1996-12-06 1997-06-05 Pfizer Prod Inc Derivados de 6-fenil piridil - 2 amina
UA64740C2 (uk) * 1997-02-10 2004-03-15 Пфайзер Продактс Інк. Похідні 2-амінопіридинів, фармацевтична композиція на їх основі (варіанти), спосіб лікування (варіанти), спосіб інгібування nos у ссавця та проміжні сполуки (варіанти)
HN1998000118A (es) 1997-08-27 1999-02-09 Pfizer Prod Inc 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
US20010049379A1 (en) 1997-08-27 2001-12-06 Lowe John Adams 2-aminopyridines containing fused ring substituents
HN1998000125A (es) 1997-08-28 1999-02-09 Pfizer Prod Inc 2-aminopiridinas con sustituyentes alcoxi ramificados
DE19806348A1 (de) * 1998-02-12 1999-08-19 Schering Ag 3,4-Dihydrochinolin-Derivate und ihre Verwendung in Arzneimitteln
ATE287876T1 (de) 1998-06-03 2005-02-15 Pfizer Prod Inc 2-aminopyridine mit kondensierten ringsubstituenten als stickstoff-oxid-synthase inhibitoren
AR019190A1 (es) * 1998-07-08 2001-12-26 Sod Conseils Rech Applic Derivados de 2-aminopiridinas, productos intermedios para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y su uso para preparar medicamentos
IL141031A0 (en) * 1998-08-11 2002-02-10 Pfizer Prod Inc New pharmaceutical uses for nos inhibitors
DE19845830A1 (de) * 1998-09-24 2000-03-30 Schering Ag Aminoalkyl-3,4-dihydrochinolin-Derivate und ihre Verwendung in Arzneimitteln
SE9803710L (sv) 1998-09-25 2000-03-26 A & Science Invest Ab Användning av vissa substanser för behandling av nervrotsskador
US7115557B2 (en) 1998-09-25 2006-10-03 Sciaticon Ab Use of certain drugs for treating nerve root injury
SE9803518D0 (sv) * 1998-10-15 1998-10-15 Astra Pharma Prod Novel compounds
PL347584A1 (en) 1998-11-13 2002-04-08 Schering Ag Fluorinated 3,4-dihydroquinoline derivatives used as nos inhibitors
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
DE60014216T2 (de) 1999-02-24 2006-03-02 F. Hoffmann-La Roche Ag 4-Phenylpyridinderivate und deren Verwendung als NK-1 Rezeptorantagonisten
KR20010114213A (ko) 1999-02-25 2001-12-31 실버스타인 아써 에이. 접합 고리 치환기를 함유한 2-아미노피리딘
US6344358B1 (en) * 1999-05-28 2002-02-05 Fujisawa Pharmaceutical Co., Ltd. Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property
SE9904765D0 (sv) 1999-12-23 1999-12-23 Astra Ab Pharmaceutically-useful compounds
IL145209A0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
CA2443868C (en) 2001-04-10 2011-01-25 Ortho-Mcneil Pharmaceutical, Inc. 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
US20030232739A1 (en) * 2001-08-15 2003-12-18 Pfizer Inc. Pharmaceutical combinations comprising a NOS inhibitor and an NMDA receptor antagonist
US6514960B1 (en) 2001-08-27 2003-02-04 Hedonist Biochemical Technologies Co., Ltd. Use of bismuth subgallate in inhibition of production of nitric oxide synthase
US6803470B2 (en) 2001-10-10 2004-10-12 Pfizer Inc 2-amino-6-(2,4,5-substituted-phenyl)-pyridines
DOP2002000467A (es) * 2001-10-10 2003-04-15 Pfizer Prod Inc 2-amino-6 (fenilo sustituido en las posiciones 2,4,5)-piridinas
US20040077853A1 (en) * 2001-10-10 2004-04-22 Pfizer Inc. 2-amino-6-(2,4,5-substituted-phenyl)-pyridines
AU2003241398A1 (en) * 2002-05-06 2003-11-17 Washington University Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
GB0218326D0 (en) * 2002-08-07 2002-09-11 Glaxo Group Ltd Compounds
EP1601674B1 (en) 2002-09-09 2012-08-08 Janssen Pharmaceutica NV Hydroxyalkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
WO2004052857A1 (en) * 2002-12-10 2004-06-24 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives as muscarinic receptor antagonists
US7288658B2 (en) 2003-07-15 2007-10-30 Hoffmann-La Roche Inc. Process for preparation of pyridine derivatives
WO2005007627A1 (ja) * 2003-07-18 2005-01-27 Nihon Nohyaku Co., Ltd. フェニルピリジン誘導体、その中間体及びこれを有効成分とする除草剤
KR20060095865A (ko) * 2003-10-14 2006-09-04 화이자 프로덕츠 인크. 글리신 수송 억제제로서의 비시클릭 [3.1.0] 유도체
US20080070952A1 (en) * 2005-02-21 2008-03-20 Proximagen Ltd., Inhibition or Treatment of Dyskinesia
US20090253765A1 (en) * 2005-05-17 2009-10-08 Santen Pharmaceutical Co., Ltd. Angiogenesis Inhibitor Containing Amine Derivative as Active Ingredient
EP2143431A1 (en) * 2005-05-17 2010-01-13 Santen Pharmaceutical Co., Ltd. Protective agent for neurocyte comprising amidino derivative as active ingredient
ATE453384T1 (de) 2005-09-23 2010-01-15 Hoffmann La Roche Neue dosierformulierung
EP2027087A2 (en) * 2006-05-18 2009-02-25 MannKind Corporation Intracellular kinase inhibitors
AU2007325355A1 (en) 2006-11-28 2008-06-05 Janssen Pharmaceutica N.V. Salts of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl) -1,3,8-triaza-spiro[4.5]decan-4-one
EP2150552B1 (en) 2007-04-09 2013-01-02 Janssen Pharmaceutica NV 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression
KR20150066608A (ko) * 2007-12-07 2015-06-16 버텍스 파마슈티칼스 인코포레이티드 사이클로알킬카복시아미도-피리딘 벤조산의 제조 방법
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
US9133116B2 (en) 2010-09-28 2015-09-15 Panacea Biotec Ltd. Bicyclic compounds
US20130281702A1 (en) * 2012-04-24 2013-10-24 Jonathan P. Pease Methods For Preparing Fentanyl And Fentanyl Intermediates
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
KR101612179B1 (ko) * 2013-04-19 2016-04-12 영남대학교 산학협력단 아미도피리딘올 유도체 또는 이의 약제학적 허용가능한 염을 유효성분으로 함유하는 암질환 예방 또는 치료용 약학조성물
US10759791B2 (en) * 2014-11-04 2020-09-01 Northwestern University Mammalian and bacterial nitric oxide synthase inhibitors
US10800773B2 (en) * 2016-09-12 2020-10-13 Integral Health, Inc. Monocyclic compounds useful as GPR120 modulators
EP3509588B1 (en) 2016-09-12 2023-06-07 Integral Health,Inc. Bicyclic compounds useful as gpr120 modulators
IL297530B2 (en) * 2017-02-28 2025-04-01 Morphic Therapeutic Inc (Alpha–V)(beta–6) integrin inhibitors
AU2018227417B2 (en) 2017-02-28 2021-12-23 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
EP4086254B1 (en) 2018-08-29 2024-12-18 Morphic Therapeutic, Inc. Integrin inhibitors
US12213973B2 (en) 2021-10-18 2025-02-04 Northwestern University Bacterial nitric oxide synthase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK40192D0 (da) * 1992-03-26 1992-03-26 Neurosearch As Imidazolforbindelser, deres fremstilling og anvendelse
DE4241801A1 (de) * 1992-12-11 1994-06-16 Bernhard Icking Vorrichtung zum Aufschluß von stärke- und/oder zuckerhaltigen Rohstoffen
WO1994014780A1 (en) * 1992-12-18 1994-07-07 The Wellcome Foundation Limited Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
ATE177078T1 (de) * 1993-10-21 1999-03-15 Searle & Co Amidino-derivate als no-synthetase inhibitoren
US5629322A (en) * 1994-11-15 1997-05-13 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase
AU4515696A (en) * 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
TR199801930T2 (xx) * 1996-03-29 1998-12-21 Pfizer Inc. 6-Fenilpiridil-2-amin t�revleri.
HN1997000027A (es) * 1996-12-06 1997-06-05 Pfizer Prod Inc Derivados de 6-fenil piridil - 2 amina

Also Published As

Publication number Publication date
TR199801930T2 (xx) 1998-12-21
GT199700033A (es) 1998-09-10
DK0891332T3 (da) 2004-07-05
ES2214604T3 (es) 2004-09-16
AU729129B2 (en) 2001-01-25
BG102872A (en) 1999-11-30
IS4823A (is) 1998-08-13
CA2250372C (en) 2005-06-21
EP0891332A1 (en) 1999-01-20
PE55098A1 (es) 1998-10-07
CZ261498A3 (cs) 1999-08-11
AP677A (en) 1998-09-25
HUP9902455A3 (en) 2000-06-28
JP3455229B2 (ja) 2003-10-14
IL125811A0 (en) 1999-04-11
HUP9902455A2 (hu) 1999-11-29
OA10873A (en) 2001-09-27
ID17116A (id) 1997-12-04
CN1546470A (zh) 2004-11-17
EA002270B1 (ru) 2002-02-28
ZA972689B (en) 1998-09-28
DE69728138D1 (de) 2004-04-22
NZ326874A (en) 2000-01-28
AU1554897A (en) 1997-10-22
MY118283A (en) 2004-09-30
CN1168719C (zh) 2004-09-29
UA49006C2 (uk) 2002-09-16
KR100313641B1 (ko) 2002-02-19
AP9700954A0 (en) 1997-04-30
WO1997036871A1 (en) 1997-10-09
DZ2197A1 (fr) 2002-12-02
EP1471055A1 (en) 2004-10-27
HK1018780A1 (en) 2000-01-07
NZ500927A (en) 2004-11-26
SK113998A3 (en) 2001-05-10
BG64310B1 (bg) 2004-09-30
CZ291647B6 (cs) 2003-04-16
ATE261942T1 (de) 2004-04-15
NO312460B1 (no) 2002-05-13
IL125811A (en) 2003-01-12
DE69728138T2 (de) 2004-09-16
EA199800772A1 (ru) 1999-04-29
CA2250372A1 (en) 1997-10-09
PT891332E (pt) 2004-07-30
HRP970174B1 (en) 2002-06-30
PL329195A1 (en) 1999-03-15
JPH11510513A (ja) 1999-09-14
AR006391A1 (es) 1999-08-25
MA26424A1 (fr) 2004-12-20
US20010034348A1 (en) 2001-10-25
BR9708386A (pt) 1999-08-03
TW438793B (en) 2001-06-07
CN1215391A (zh) 1999-04-28
UY24503A1 (es) 2000-09-29
TNSN97055A1 (fr) 2005-03-15
US6235747B1 (en) 2001-05-22
KR20000005127A (ko) 2000-01-25
EP0891332B1 (en) 2004-03-17
NO984516D0 (no) 1998-09-28
NO984516L (no) 1998-09-28
SI0891332T1 (en) 2004-06-30
US6465491B2 (en) 2002-10-15
HRP970174A2 (en) 2000-12-31
YU12097A (en) 1999-11-22

Similar Documents

Publication Publication Date Title
CO4650042A1 (es) Derivados de 6-fenilpiridil-2-amina
NZ502281A (en) 2-aminopyridines containing fused ring substituents as nitric oxide synthase (NOS) inhibitors
AR010331A1 (es) Compuestos derivados de 6-fenilpiridil-2-amina utiles como inhibidores nos, composiciones farmaceuticas que comprenden dichos compuestos, y metodosde tratamiento utilizando dichos compuestos.
CO4970713A1 (es) Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
AR025735A1 (es) Compuestos terapeuticos
AR034897A1 (es) Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos
AR011117A1 (es) 2-amino-6-(4-fenoxi-2-sustituido)-piridinas sustituidas, composiciones farmaceuticas que las contienen, compuestos intermediarios para producirlas y uso de los compuestos en la preparacion de medicamentos.
CO5261632A1 (es) Inhibidores de la recaptacion de monoamidas para el tratamiento del snc
AR030959A1 (es) Derivados de aminoalcoholes, procedimiento para prepararlos, el uso de los mismos para preparar medicamentos y las composiciones farmaceuticas que las contienen
AR013094A1 (es) Compuestos de urea n-sustituida,composicion farmaceutica y uso de dichos compuestos para preparar medicamentos
UY26132A1 (es) Compuestos de pirimidinona y usos para tratamiento de la arterosclerosis
IE891797L (en) 4-amino quinolines and naphthyridines, process for their¹preparation and their use as medicines
BR1100061A (pt) Composto, processo para a preparação do mesmo, composição e uso dos mesmos
AR024918A1 (es) Derivados de ciclobuteno, su preparacion y sus usos terapeuticos.
CO5160242A1 (es) UTILIZACION DE DERIVADOS DE PIRIDAZINO [4,5-b] INDOL-1- ACETAMIDA, PARA LA PREPARACION DE MEDICAMENTOS DESTINADOS A LAS ENFERMEDADES DEL SISTEMA NERVIOSO CENTRAL
ES2172173T3 (es) 2-aminopiridinas con sustituyentes alcoxi ramificados como inhibidores de la nos.
ES8707541A1 (es) Un procedimiento para la preparacion de derivados de cefalosporina
MX9306310A (es) Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
BG105855A (en) 2-aminopyridines containing fused ring substituents
ES2154453T3 (es) Compuestos pertenecientes a la familia de los amidiniums, composiciones farmaceuticas que les contienen y sus aplicaciones.
DK219488D0 (da) Benzo- og thieno-3,4-dihydropyridinderivater, deres fremstilling og laegemidler indeholdende forbindelserne
AR027454A1 (es) Derivados de beta-alanina, utiles como antagonistas de receptores, las composiciones farmaceuticas que las contienen y el uso de los mismos para lapreparacion de medicamentos
ES2172376B1 (es) Nuevos derivados de isoquinoleinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR021970A1 (es) Inhibidores de proteasas
AR017260A1 (es) Derivados de eritromicina 6-0-sustituida de 3-descladinosa, composicion farmaceutica que los contiene, su uso para la manufactura de un medicamento y procedimiento para su preparacion